Meta-analysis of studies examining medication adherence, persistence, and discontinuation of oral antihyperglycemic agents in type 2 diabetes

References

• International Diabetes Federation. IDF Diabetes Atlas update poster, 6th edn. Brussels, Belgium: International Diabetes Federation, 2014
   Google Scholar
• International Diabetes Federation. IDF Diabetes Atlas, 6th edn. Brussels, Belgium: International Diabetes Federation, 2013. Available at: http://www.idf.org/diabetesatlas
   Google Scholar
• The UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 1998;352:837-53
   PubMed Web of Science ®Google Scholar
• Holman RR, Paul SK, Bethel MA, et al. 10-year follow-up of intensive glucose control in type 2 diabetes. N Engl J Med 2008;359:1577-89
   PubMed Web of Science ®Google Scholar
• The ADVANCE Collaborative Group. Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N Engl J Med 2008;358:2560-72
   PubMed Web of Science ®Google Scholar
• Asche C, LaFleur J, Conner C. A review of diabetes treatment adherence and the association with clinical and economic outcomes. Clin Ther 2011;33:74-109
   PubMed Web of Science ®Google Scholar
• Odegard PS, Capoccia K. Medication taking and diabetes: a systematic review of the literature. Diabetes Educ 2007;33:1014-29
   PubMed Web of Science ®Google Scholar
• Curkendall SM, Thomas N, Bell KF, et al. Predictors of medication adherence in patients with type 2 diabetes mellitus. Curr Med Res Opin 2013;29:1275-86
   PubMed Web of Science ®Google Scholar
• Osterberg L, Blaschke T. Adherence to medication. N Engl J Med 2005;353:487-97
   PubMed Web of Science ®Google Scholar
• Liberati A, Altman DG, Tetzlaff J, et al. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate healthcare interventions: explanation and elaboration. BMJ 2009;339:b2700
   PubMed Web of Science ®Google Scholar
• Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.0.2 [updated September 2009]. The Cochrane Collaboration, 2009. Available at: www.cochrane-handbook.org [Last accessed 20 December 2014]
   Google Scholar
• Effective Public Health Practice Project. Quality Assessment Tool For Quantitative Studies. Hamilton, ON: Effective Public Health Practice Project. 1998. Available at: http://www.ephpp.ca/index.html
   Google Scholar
• Egger M, Davey SG, Schneider M, Minder C. Bias in meta-analysis detected by a simple, graphical test. BMJ 1997;315:629-34
   PubMed Web of Science ®Google Scholar
• Amiche MA, Guenette L, Gregoire JP, Moisan J. Adherence to antidiabetic drug treatment among workers with type 2 diabetes. J Popul Ther Clin Pharmacol 2012;19:e115-16
   Google Scholar
• Balkrishnan R, Rajagopalan R, Shenolikar RA, et al. Outcomes associated with introduction of thiazolidinedione therapy in Medicaid enrolled patients with type 2 diabetes: an updated and expanded retrospective analysis. Curr Med Res Opin 2006;22:551-9
   PubMed Web of Science ®Google Scholar
• Barner JC. Adherence to oral antidiabetic agents with pioglitazone and metformin: comparison of fixed-dose combination therapy with monotherapy and loose-dose combination therapy. Clin Ther 2011;33:1281-8
   PubMed Web of Science ®Google Scholar
• Barron J, Wahl P, Fisher M, Plauschinat C. Effect of prescription copayments on adherence and treatment failure with oral antidiabetic medications. PT 2008;33:532-53
   PubMedGoogle Scholar
• Blonde L, Wogen J, Kreilick C, Seymour AA. Greater reductions in A1C in type 2 diabetic patients new to therapy with glyburide/metformin tablets as compared to glyburide co-administered with metformin. Diabetes Obes Metab 2003;5:424-31
   PubMed Web of Science ®Google Scholar
• Cheong C, Barner JC, Lawson KA, Johnsrud MT. Patient adherence and reimbursement amount for antidiabetic fixed-dose combination products compared with dual therapy among Texas Medicaid recipients. Clin Ther 2008;30:1893-907
   PubMed Web of Science ®Google Scholar
• Hansen RA, Farley JF, Droege M, Maciejewski ML. A retrospective cohort study of economic outcomes and adherence to monotherapy with metformin, pioglitazone, or a sulfonylurea among patients with type 2 diabetes mellitus in the United States from 2003 to 2005. Clin Ther 2010;32:1308-19
   PubMed Web of Science ®Google Scholar
• Haupt D, Weitoft GR, Nilsson JL. Refill adherence to oral antihyperglycaemic drugs in Sweden. Acta Diabetol 2009;46:203-8
   PubMed Web of Science ®Google Scholar
• Hertz RP, Unger AN, Lustik MB. Adherence with pharmacotherapy for type 2 diabetes: a retrospective cohort study of adults with employer-sponsored health insurance. Clin Ther 2005;27:1064-73
   PubMed Web of Science ®Google Scholar
• Kalsekar ID, Madhavan SS, Amonkar MM, et al. Depression in patients with type 2 diabetes: impact on adherence to oral hypoglycemic agents. Ann Pharmacother 2006;40:605-11
   PubMed Web of Science ®Google Scholar
• Kasliwal R, Wilton LV, Shakir SA. Monitoring the safety of pioglitazone: results of a prescription-event monitoring study of 12,772 patients in England. Drug Saf 2008;31:839-50
   PubMed Web of Science ®Google Scholar
• Kim N, Agostini J, Justice A. Measuring persistence to oral hypoglycemic agents in type 2 diabetic veterans. J Pharm Technol 2009;25:223-9
   PubMedGoogle Scholar
• Lafata JE, Dobie EA, Divine GW, et al. Sustained hyperglycemia among patients with diabetes: what matters when action is needed? Diabetes Care 2009;32:1447-52
   PubMed Web of Science ®Google Scholar
• Lamberts EJ, Nijpels G, Welschen LM, et al. Discontinuation of statins among patients with type 2 diabetes. Diabetes Metab Res Rev 2012;28:241-5
   PubMed Web of Science ®Google Scholar
• Lau DT, Nau DP. Oral antihyperglycemic medication nonadherence and subsequent hospitalization among individuals with type 2 diabetes. Diabetes Care 2004;27:2149-53
   PubMed Web of Science ®Google Scholar
• Nau DP, Chao J, Aikens JE. The relationship of guideline-concordant depression treatment and patient adherence to oral diabetes medications. Res Social Adm Pharm 2005;1:378-88
   PubMedGoogle Scholar
• Nichols GA, Conner C, Brown JB. Initial nonadherence, primary failure and therapeutic success of metformin monotherapy in clinical practice. Curr Med Res Opin 2010;26:2127-35
   PubMed Web of Science ®Google Scholar
• Patel I, Chang J, Shenolikar RA, Balkrishnan R. Medication adherence in low income elderly type-2 diabetes patients: a retrospective cohort study. Int J Diabetes Mellitus 2010;2:122-4
   Google Scholar
• Penning-van Beest FJ, van der Bij S, Erkens JA, et al. Effect of non-persistent use of oral glucose-lowering drugs on HbA1c goal attainment. Curr Med Res Opin 2008;24:2523-9
   PubMed Web of Science ®Google Scholar
• Plat A, Penning-van BF, Kessabi S, et al. Change of initial oral antidiabetic therapy in type 2 diabetic patients. Pharm World Sci 2009;31:622-6
   PubMed Web of Science ®Google Scholar
• Pollack M, Chastek B, Williams SA, Moran J. Impact of treatment complexity on adherence and glycemic control: an analysis of oral antidiabetic agents. J Clin Outcomes Manage 2010;17:20-30
   Google Scholar
• Rathmann W, Kostev K, Gruenberger JB, et al. Treatment persistence, hypoglycaemia and clinical outcomes in type 2 diabetes patients with dipeptidyl peptidase-4 inhibitors and sulphonylureas: a primary care database analysis. Diabetes Obes Metab 2013;15(1):55-61
   PubMed Web of Science ®Google Scholar
• Rozenfeld Y, Hunt JS, Plauschinat C, Wong KS. Oral antidiabetic medication adherence and glycemic control in managed care. Am J Manag Care 2008;14:71-5
   PubMed Web of Science ®Google Scholar
• Virdi N, Daskiran M, Nigam S, et al. The association of self-monitoring of blood glucose use with medication adherence and glycemic control in patients with type 2 diabetes initiating non-insulin treatment. Diabetes Technol Ther 2012;14:790-8
   PubMed Web of Science ®Google Scholar
• Voorham J, Haaijer-Ruskamp FM, Wolffenbuttel BH, et al. Medication adherence affects treatment modifications in patients with type 2 diabetes. Clin Ther 2011;33:121-34
   PubMed Web of Science ®Google Scholar
• Wong MC, Kong AP, So WY, et al. Pharmacoepidemiological profiles of oral hypoglycemic agents among 28,773 Chinese patients with diabetes. Diabetes Res Clin Pract 2012;96:319-25
   PubMed Web of Science ®Google Scholar
• Zhang Q, Zhao C, Davies MJ, et al. Compliance and persistence with concomitant statin and oral antihyperglycemic therapy. Am J Manag Care 2011;17:746-52
   PubMed Web of Science ®Google Scholar
• Feinbock C, Luger A, Klingler A, et al. Prospective multicentre trial comparing the efficacy of, and compliance with, glimepiride or acarbose treatment in patients with type 2 diabetes not controlled with diet alone. Diabetes Nutr Metab 2003;16:214-21
   PubMedGoogle Scholar
• Filozof C, Gautier JF. A comparison of efficacy and safety of vildagliptin and gliclazide in combination with metformin in patients with type 2 diabetes inadequately controlled with metformin alone: a 52-week, randomized study. Diabet Med 2010;27:318-26
   PubMed Web of Science ®Google Scholar
• Goldstein BJ, Rosenstock J, Anzalone D, et al. Effect of tesaglitazar, a dual PPAR alpha/gamma agonist, on glucose and lipid abnormalities in patients with type 2 diabetes: a 12-week dose-ranging trial. Curr Med Res Opin 2006;22:2575-90
   PubMed Web of Science ®Google Scholar
• Jain R, Osei K, Kupfer S, et al. Long-term safety of pioglitazone versus glyburide in patients with recently diagnosed type 2 diabetes mellitus. Pharmacotherapy 2006;26:1388-95
   PubMed Web of Science ®Google Scholar
• Pfutzner A, Paz-Pacheco E, Allen E, et al. Initial combination therapy with saxagliptin and metformin provides sustained glycaemic control and is well tolerated for up to 76 weeks. Diabetes Obes Metab 2011;13:567-76
   PubMed Web of Science ®Google Scholar
• Taskinen MR, Rosenstock J, Tamminen I, et al. Safety and efficacy of linagliptin as add-on therapy to metformin in patients with type 2 diabetes: a randomized, double-blind, placebo-controlled study. Diabetes Obes Metab 2011;13:65-74
   PubMed Web of Science ®Google Scholar
• Truitt KE, Goldberg RB, Rosenstock J, et al. A 26-week, placebo- and pioglitazone-controlled, dose-ranging study of rivoglitazone, a novel thiazolidinedione for the treatment of type 2 diabetes. Curr Med Res Opin 2010;26:1321-31
   PubMed Web of Science ®Google Scholar
• Cramer JA, Benedict A, Muszbek N, et al. The significance of compliance and persistence in the treatment of diabetes, hypertension and dyslipidaemia: a review. Int J Clin Pract 2008;62:76-87
   PubMed Web of Science ®Google Scholar
• Nam S, Chesla C, Stotts NA, et al. Barriers to diabetes management: patient and provider factors. Diabetes Res Clin Pract 2011;93:1-9
   PubMed Web of Science ®Google Scholar
• Tiv M, Viel JF, Mauny F, et al. Medication adherence in type 2 diabetes: the ENTRED study 2007, a French population-based study. PLoS One 2012;7:e32412
   PubMed Web of Science ®Google Scholar
• Donnan PT, MacDonald TM, Morris AD. Adherence to prescribed oral hypoglycaemic medication in a population of patients with type 2 diabetes: a retrospective cohort study. Diabet Med 2002;19:279-84
   PubMed Web of Science ®Google Scholar
• Cramer JA, Roy A, Burrell A, et al. Medication compliance and persistence: terminology and definitions. Value Health 2008;11:44-7
   PubMed Web of Science ®Google Scholar
• Raebel MA, Schmittdiel J, Karter AJ, et al. Standardizing terminology and definitions of medication adherence and persistence in research employing electronic databases. Med Care 2013;51(8 Suppl 3):S11-21
   PubMed Web of Science ®Google Scholar
• Fu R, Gartlehner G, Grant M, et al. Conducting quantitative synthesis when comparing medical interventions: AHRQ and the Effective Health Care Program. J Clin Epidemiol 2011;64:1187-97
   PubMed Web of Science ®Google Scholar